StocksMedium•24 October 2026•
1 min read
Vertex Reports Positive Phase III Results for Kidney Disease Treatment
Key Facts
1Povetacicept reduced proteinuria by 52% at 36 weeks in a Phase III trial for IgA nephropathy.
Vertex Pharmaceuticals reported positive interim Phase III data for its kidney disease drug povetacicept, showing significant reduction in disease biomarkers. Yahoo Finance reported that the drug reduced proteinuria by 52% at 36 weeks in a clinical trial for IgA nephropathy. The company stated that the results demonstrate the potential efficacy of the treatment for patients suffering from this condition.
The company is targeting a kidney disease pipeline that it estimates represents a potential $10 billion market opportunity. The successful trial results underscore the company's progress in developing high-value clinical assets within the biotechnology sector.